Business Description

Description
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Name Current Vs Industry Vs History
Cash-To-Debt 0.08
Equity-to-Asset 0.43
Debt-to-Equity 0.89
Debt-to-EBITDA 3.07
Interest Coverage 1.76
Piotroski F-Score 7/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.03
Distress
Grey
Safe
Beneish M-Score -2.62
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
6-1 Month Momentum % 33.85
12-1 Month Momentum % 5.13

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.6
Quick Ratio 1.06
Cash Ratio 0.23
Days Inventory 139.59
Days Sales Outstanding 72.93
Days Payable 46.01

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -33
Shareholder Yield % 28.4

Financials (Next Earnings Date:2024-02-27 Est.)

XTAE:MYL's 30-Y Financials
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Viatris Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil ₪) 57,243.584
EPS (TTM) (₪) 0
Beta 0
Volatility % 0
14-Day RSI 0
14-Day ATR (₪) 0
20-Day SMA (₪) 0
12-1 Month Momentum % 5.13
52-Week Range (₪) 105.2 - 168.4
Shares Outstanding (Mil) 536.44

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 7
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Viatris Inc Filings

Filing Date Document Date Form
No Filing Data

Viatris Inc Stock Events

Event Date Price(₪)
No Event Data

Viatris Inc Frequently Asked Questions

What is Viatris Inc(XTAE:MYL)'s stock price today?
The current price of XTAE:MYL is ₪142.10. The 52 week high of XTAE:MYL is ₪168.40 and 52 week low is ₪105.20.
When is next earnings date of Viatris Inc(XTAE:MYL)?
The next earnings date of Viatris Inc(XTAE:MYL) is 2024-02-27 Est..
Does Viatris Inc(XTAE:MYL) pay dividends? If so, how much?
Viatris Inc(XTAE:MYL) does not pay dividend.

Press Release

Subject Date
No Press Release